Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Capital Expenditures (2020 - 2025)

Barinthus Biotherapeutics filings provide 6 years of Capital Expenditures readings, the most recent being $32000.0 for Q2 2025.

  • On a quarterly basis, Capital Expenditures fell 83.33% to $32000.0 in Q2 2025 year-over-year; TTM through Mar 2026 was $32000.0, a 94.57% decrease, with the full-year FY2025 number at $37000.0, down 95.85% from a year prior.
  • Capital Expenditures hit $32000.0 in Q2 2025 for Barinthus Biotherapeutics, up from $5000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $5.1 million in Q3 2023 to a low of -$5.5 million in Q4 2023.
  • Median Capital Expenditures over the past 5 years was $350000.0 (2021), compared with a mean of $461111.1.
  • Biggest five-year swings in Capital Expenditures: surged 1681.82% in 2021 and later plummeted 1034.98% in 2023.
  • Barinthus Biotherapeutics' Capital Expenditures stood at $424000.0 in 2021, then soared by 38.21% to $586000.0 in 2022, then plummeted by 1034.98% to -$5.5 million in 2023, then surged by 105.07% to $278000.0 in 2024, then tumbled by 88.49% to $32000.0 in 2025.
  • The last three reported values for Capital Expenditures were $32000.0 (Q2 2025), $5000.0 (Q1 2025), and $278000.0 (Q4 2024) per Business Quant data.